Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 13,900 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Trial Clear all

Conditions: Overweight, Obesity
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 2,539 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 54
States / cities: Pelham, Alabama • Scottsdale, Arizona • Concord, California + 47 more

Conditions: Urinary Tract Infection(UTI), Antimicrobial Stewardship, Primary Care
Interventions: MSCC Educational Tool; Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Asthma
Interventions: Tiotropium low dose QD, Tiotropium high dose QD, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 6
States / cities: Columbia, Missouri • Cincinnati, Ohio • Oklahoma City, Oklahoma + 3 more

Conditions: Peripheral Arterial Disease, Claudication (Finding)
Interventions: Cilostazol; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 35 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Sickle Cell Disease, Sickle Cell Trait
Interventions: CHOICES, eBook; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 45 Years
Enrollment: 506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Laceration
Interventions: Absorbable Sutures, Steri-Strips, Dermabond; Procedure
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: Up to 18 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Overactive Bladder (OAB)
Interventions: NT 201 200U and Vibe System, NT 201 300U and Vibe System, Placebo and sham; Combination Product
Lead sponsor: Vensica Therapeutics Ltd.; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Margate, Florida • Pompano Beach, Florida • Reno, Nevada

Conditions: Airway Management
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: Not listed
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Pain, Regional Anesthesia Morbidity
Interventions: ropivacaine, bupivacaine, Sham Adductor Canal Catheter, Adductor Canal Catheter; Drug · Device
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 40 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Parkinson's Disease Psychosis
Interventions: Pimavanserin tartrate (ACP-103), Placebo; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 36
States / cities: Gilbert, Arizona • Phoenix, Arizona • Berkeley, California + 33 more

Conditions: Breast Cancer With Chronic Lymphedema
Interventions: Acupuncture, Wait-list; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Neoplasms
Interventions: Re-Patterning Sitting Time Group, Reducing Sitting Time Group, Usual Care; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Facial Laceration
Interventions: Dermabond and steristrips, Dermabond; Procedure
Lead sponsor: University of Texas at Austin; Other
Eligibility: Up to 17 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Phantom Limb Pain, Phantom Pain, Phantom Sensation, Phantom Limb Syndrome With Pain, Phantom Pain Following Amputation of Lower Limb, Phantom Pain Following Amputation of Upper Limb, Amputation, Upper Limb Amputation at the Hand, Upper Limb Amputation at the Wrist, Upper Limb Amputation Below Elbow (Injury), Upper Limb Amputation Above Elbow (Injury), Lower Limb Amputation Knee, Lower Limb Amputation Above Knee (Injury), Lower Limb Amputation Below Knee (Injury), Lower Limb Amputation at Ankle (Injury)
Interventions: Coapt Phantom Limb Pain Management System; Device
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Nausea
Interventions: Saline, Phenergan; Drug
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Posttraumatic Stress Disorder
Interventions: Interpersonal Therapy for PTSD, Prolonged Exposure; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: New Orleans, Louisiana • Providence, Rhode Island

Conditions: Oral Mucositis
Interventions: ALD518, 0.9% saline; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Clearwater, Florida • Boston, Massachusetts • Detroit, Michigan + 10 more

Conditions: Renal Insufficiency, Chronic, Food Insecurity
Interventions: Produce Prescription; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Knee Injuries, Shoulder Injuries, Rotator Cuff Disease, Meniscus Tear, Patellofemoral Pain
Interventions: eRehab, Formal Physical Therapy; Other
Lead sponsor: Charlotte Sports Medicine Institute, PA; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Prince Frederick, Maryland • Charlotte, North Carolina

Conditions: Alcohol Use Disorder
Interventions: Semaglutide 3 MG [Rybelsus], Semaglutide 7 MG [Rybelsus], Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Overactive Bladder (OAB), Urinary Urgency, Urinary Urge Incontinence (UUI), Nocturia, Urinary Frequency
Interventions: RiSolve App, AUGS Patient Handouts; Device · Behavioral
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 22 Years and older · Female only
Enrollment: 596 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 10
States / cities: Birmingham, Alabama • Palo Alto, California • Washington D.C., District of Columbia + 7 more

Conditions: Hepatocellular Carcinoma, Liver Cancer, HCC
Interventions: MLN0128, MLN0128 (RP2D), Sorafenib; Drug
Lead sponsor: Kathy Miller; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 6
States / cities: Chicago, Illinois • Indianapolis, Indiana • Chapel Hill, North Carolina + 2 more

Conditions: Heart Failure
Interventions: Values Affirmation + Usual Care, Usual Care; Behavioral · Other
Lead sponsor: The Miriam Hospital; Other
Eligibility: 50 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Prostate Cancer
Interventions: avodart, Placebo; Drug
Lead sponsor: Bay State Clinical Trials, Inc.; Other
Eligibility: 35 Years to 90 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Watertown, Massachusetts

Search by objective public record fields.

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

Diagnostic Stewardship Intervention to Reduce Inappropriate Antibiotic Use for Urinary Tract Infections in Primary Care

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma

Cilostazol After Lower Extremity Arterial Revascularization Trial

CHOICES3: Sickle Cell Disease Parenting CHOICES

Trial Comparing Cosmetic Outcomes of Pediatric Laceration Closure Using Skin Glue, Medical Tape Versus Stitches

RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of Idiopathic Overactive Bladder

Spatial Orientation and Fiberoptic Intubation Skills in the Novice: A Randomized Controlled Trial

Adductor Canal Catheter vs Local Infiltration of Analgesia for Total Knee Arthroplasty

A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Acupuncture for Chronic Lymphedema

The Plan and Stand Study: Reducing Sitting Time in Breast Cancer Survivors

Facial Lacerations Repaired With Dermabond Compared With Dermabond With Underlying Steristrips in Pediatric Patients

VR to Evaluate Phantom Limb Pain

Prevention of Narcotic-Induced Nausea

Comparative Effectiveness of Two Treatments for Veterans With PTSD

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

Penn Produce Prescription and Chronic Kidney Disease Study

Internet Enhanced, Patient-Centered Orthopedic Care: A Prospective, Randomized, Controlled Pilot Trial

Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)

APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women

MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

Values-Affirmation + Education Intervention Targeting Medication Adherence in Older Adults With Heart Failure

Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation